RBC Capital analyst Brian Abrahams kept his Outperform rating on Intercept (ICPT) after its Regenerate data in the 25mg obeticholic acid, or OCA, study and the subsequent 13% decline in its stock price. The analyst believes that the sell-off was in part a "sell the news" event and also may have been driven by the separately announced 20% sales force layoff at Gilead (GILD), which had been viewed as a potential buyer of NASH assets. Abrahams maintains his view on OCA's benefit/risk profile as "solid", adding that while fundamental concerns around the launch and necessary capital are likely to remain, he expects its "likely approval and broad long-term market opportunity" to become "better appreciated in the medium-term."